Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038467 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,740
- Enrollment target
NCT00038467 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 4,740 participants.
The verdict
NCT00038467, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,740 participants
- Enrollment target
Study Summary
To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.
Interventions
- DRUG Tamoxifen
- DRUG Exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,740 participants |
| Start Date | 1998-02 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038467
The ClinicalTrials.gov registry entry for NCT00038467 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,740 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT00038467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038467 about?
NCT00038467 is a clinical study titled "Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer". To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of co...
What is the current status of trial NCT00038467?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,740 participants. The study started on 1998-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00038467?
The interventions under investigation include: Tamoxifen (DRUG), Exemestane (DRUG).
Who is sponsoring clinical trial NCT00038467?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.